6 Of Goldman Sachs Top 2024 Stock Picks Also Pay Big Dividends Chris Hondros / Getty Images The Artificial Intelligence rally over the last year, led by the so-called “Magnificent 7,” has been fantastic if you owned those stocks. However, most of the S&P 500 is treading water and will not likely ever catch up to the hype-driven AI stocks soon.With the market trading at all-time highs, investors will likely be lured into a false sense of financial security. The reality is the United States could be set for ...

The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.10 mREITs With Impressive Yields »Amgen today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The ...

THOUSAND OAKS, Calif., March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This a ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's largest biotech drugmaker have returned -12.5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 1% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

Amgen Inc. (NASDAQ:AMGN) TD Cowen 44th Annual Health Care Conference March 5, 2024 9:10 AM ET Company Participants Peter Griffith - Chief Financial Officer Paul Burton - Chief Medical Officer Conference Call Participants Yaron Werber - TD Cowen Yaron Werber All right. Well, welcome once again to the 44th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the Biotech team, and it's a great pleasure to moderate the fireside chat next with Amgen, first fireside chat for the day, so have very high ex ...

Amgen (AMGN) ended the recent trading session at $279.35, demonstrating a -0.35% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.12%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.41%.Prior to today's trading, shares of the world's largest biotech drugmaker had lost 13.26% over the past month. This has lagged the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83% in that time.The upcoming ...

Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.This perspective often invites speculation that leads to overvaluation. Over the last three months, the SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) is up nearly 22% ...

THOUSAND OAKS, Calif., Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date. "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen. "As part of Amgen's global biomanufacturing netw ...

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next decade.Of course, investing in just any biotech stock won't do. It's important to decide whether a company has the innovative capabilities to stay relevant and continuously deliver strong returns. Let's consider three biotech stocks that have wha ...

Amgen Inc. Rare Disease Investor Analyst Call Summary Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Date of Call**: February 22, 2024 - **Focus**: Rare Disease as a new growth pillar alongside general medicine, oncology, and inflammation [3][4] Key Points and Arguments Strategic Focus on Rare Disease - Rare disease is identified as Amgen's fourth and newest growth pillar, enhancing existing opportunities in other therapeutic areas [3][4] - The acquisition of TAVNEOS and Horizon has strengthened Amgen's portfolio in rare diseases, establishing a robust growth avenue [4] Growth Projections - Anticipated sustained growth across all pillars through the end of the decade, driven by marketed products and innovative pipeline projects [5][7] - Rare disease products generated nearly $4 billion in sales in 2023, primarily in the U.S., indicating significant room for international expansion [13] Innovative Product Portfolio - Key medicines include: - **TEPEZZA**: First treatment for thyroid eye disease, addressing a critical unmet need [8] - **KRYSTEXXA**: Treatment for uncontrolled gout, showing a 70% reduction in uric acid levels in clinical trials [36][38] - **UPLIZNA**: Targets neuromyelitis optica spectrum disorder (NMOSD), with over 75% reduction in relapse risk [47] - **TAVNEOS**: First-in-class treatment for ANCA-associated vasculitis, showing superior results in sustaining remission compared to standard therapy [60][61] Market Opportunities - Rare diseases often lack treatment options, with only 5% of the estimated 10,000 rare diseases having available therapies [10] - The U.S. market for TEPEZZA has a penetration rate in the high single digits, indicating substantial growth potential [27] - International expansion is a priority, with regulatory reviews and filings underway in Japan and Europe for TEPEZZA [30][31] Patient Challenges and Support - Patients with rare diseases face significant barriers, including misdiagnosis, limited treatment options, and geographic access issues [11][12] - Amgen is committed to enhancing disease awareness and providing comprehensive support to improve patient outcomes [12] Financial Stability and Shareholder Value - Amgen's combined cash flow supports ongoing investments in innovation while delivering shareholder value through a growing dividend [7] - The strategic focus on rare diseases is expected to accelerate revenue growth and contribute to non-GAAP earnings starting in 2024 [7] Research and Development Capabilities - Amgen leverages its robust R&D capabilities and biologics manufacturing expertise to advance its rare disease portfolio [6] - The company is utilizing advanced research platforms to fill data gaps and expedite the development of rare disease medicines [67][68] Pipeline and Future Indications - Ongoing Phase 3 trials for UPLIZNA in IgG4-related disease and myasthenia gravis, with expected data readouts in the second half of 2024 [53][55] - Continued focus on expanding the rare disease portfolio and enhancing treatment options for patients [66] Additional Important Insights - The call highlighted the importance of patient advocacy and community support in addressing the unique needs of rare disease patients [16] - Amgen's commitment to innovation and patient-centric approaches positions it favorably in the rare disease market, with a strong reputation among patient advocacy groups [17] This summary encapsulates the key points discussed during the Amgen Rare Disease Investor Analyst Call, emphasizing the company's strategic focus, growth opportunities, and commitment to addressing the needs of patients with rare diseases.